Health & Biotech
Health Kick: Injectable contrast dyes have serious health impacts, Osprey Medical has the solution
Health & Biotech
MGC Pharma ready to march ahead with three clinical trials in 2021
Health & Biotech
Health Kick: CEO Rob Wong on how Control Bionics is enabling communication via brain signals
Health & Biotech
Neurotech hits another key milestone with unique drug therapy in the US$25bn market for multiple sclerosis treatments
Health & Biotech
Introducing Opin, Opyl’s AI platform that recruits clinical trial patients from around the world
Health & Biotech
‘Tidal wave of demand’: There’s a pot shortage in New York
Health & Biotech
Anteotech flags in-house scale up for its COVID-19 test kit, shares edge higher
Health & Biotech
Dr Boreham’s Crucible: Can Island Pharmaceuticals build the ultimate mozzie-zapper?
Health & Biotech
PainChek expands into infant market, with ambitions to scale globally
Experts
ScoPo’s Powerplays: Hearing tech, medical devices to ride out choppy market
Health & Biotech
Creso Pharma expands into Eastern Europe with animal product launch in Poland
Health & Biotech
Weed Week: Europe or North America, where’s the place to be for ASX cannabis stocks?
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.